术前[68Ga]Ga-FAPI-46 PET/CT评估腹膜癌病:与手术病理PCI的一致性及与MRI和[18F]FDG PET/CT的比较
这项前瞻性2期研究纳入61例结直肠癌或卵巢癌伴已知或疑似腹膜癌病患者,术前4周内行FAPI PET、FDG PET和MRI弥散加权成像,以手术病理PCI为参考标准。FAPI PET与参考标准的一致性最高(ICC 0.81),高于MRI(0.76)和FDG PET(0.54);FAPI PET节段水平灵敏度显著高于MRI和FDG PET,但特异度较低。近期化疗亚组中FAPI PET一致性仍良好(ICC 0.75)。
要点
- FAPI PET与手术病理PCI一致性最高(ICC 0.81),优于MRI和FDG PET。
- FAPI PET节段灵敏度77.6%,显著高于MRI(67.0%)和FDG PET(47.5%),但特异度较低。
- 近期化疗后FAPI PET一致性仍良好(ICC 0.75),优于MRI和FDG PET。
核心结论
- FAPI PET与手术病理PCI的总体一致性最强,检出能力高于MRI弥散加权成像和FDG PET,且化疗后性能保持,支持其用于术前腹膜癌病绘图。
研究设计与样本
- 前瞻性2期研究(FAPeCa,NCT06061874),纳入61例结直肠癌或卵巢癌伴已知或疑似腹膜癌病患者。
- 术前4周内行FAPI PET、FDG PET和MRI弥散加权成像,以诊断性腹腔镜或肿瘤细胞减灭术的手术病理为参考标准。
- 采用10段腹膜癌指数(PCI)适配法量化腹膜癌病范围,用组内相关系数(ICC)评估一致性,节段水平按PCI 0 vs ≥1二分类评估诊断性能。
主要发现
- 与参考标准的一致性:FAPI PET的ICC为0.81,MRI为0.76,FDG PET为0.54。
- 节段水平灵敏度、特异度和准确度:FAPI PET分别为77.6%、71.2%和74.8%;MRI分别为67.0%、84.4%和74.7%;FDG PET分别为47.5%、91.8%和67.2%。
- FAPI PET灵敏度显著高于MRI和FDG PET(两项比较P < 0.001),但特异度低于MRI和FDG PET。
- 近期化疗亚组中,FAPI PET一致性仍良好(ICC 0.75),MRI为0.65,FDG PET为0.46。
关键数值与推荐
- 一致性评估采用ICC:FAPI PET 0.81、MRI 0.76、FDG PET 0.54。
- 节段水平诊断性能按PCI 0 vs ≥1二分类评估,FAPI PET灵敏度77.6%、特异度71.2%、准确度74.8%。
- FAPI PET灵敏度显著高于MRI和FDG PET(P < 0.001),特异度低于两者。
- 近期化疗亚组ICC:FAPI PET 0.75、MRI 0.65、FDG PET 0.46。
临床怎么用
- FAPI PET可作为结直肠癌或卵巢癌患者术前腹膜癌病绘图工具,与手术病理PCI一致性最高。
- FAPI PET灵敏度高于MRI和FDG PET,但特异度较低,需结合其他影像综合判断。
- 近期化疗后FAPI PET一致性仍保持良好,可考虑用于化疗后患者的术前评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Accurate preoperative mapping of peritoneal carcinomatosis (PC) is critical for selecting patients for cytoreductive surgery and guiding treatment planning. Conventional imaging, including [18F]FDG PET/CT (FDG PET), may underestimate PC extent. This study evaluated [68Ga]Ga-fibroblast activation protein inhibitor (FAPI)-46 PET/CT (FAPI PET) for preoperative PC assessment, examining agreement with the surgicopathologic reference standard and comparing its performance with MRI and FDG PET. Methods: In this prospective phase 2 study (FAPeCa, NCT06061874), patients with colorectal or ovarian cancer with known or suspected PC underwent FAPI PET, FDG PET, and MRI with diffusion-weighted imaging within 4 wk before diagnostic laparoscopy or cytoreductive surgery. PC extent was quantified using a 10-segment peritoneal cancer index (PCI) adaptation. Agreement with the reference standard was assessed using intraclass correlation coefficients (ICCs), and segment-level diagnostic performance was evaluated after dichotomization (PCI, 0 vs. ≥1). Subgroup analyses were performed based on recent chemotherapy status. Results: The analysis included 61 patients. Agreement with the reference standard was highest for FAPI PET (ICC, 0.81), followed by MRI (ICC, 0.76) and FDG PET (ICC, 0.54). Segment-level sensitivity, specificity, and accuracy were 77.6%, 71.2%, and 74.8% for FAPI PET; 67.0%, 84.4%, and 74.7% for MRI; and 47.5%, 91.8%, and 67.2% for FDG PET, respectively, with significantly higher sensitivity for FAPI PET (P < 0.001 for both comparisons) but lower specificity than for MRI and FDG PET. In the recent chemotherapy subgroup, agreement remained good for FAPI PET (ICC, 0.75), compared with lower agreement for MRI (ICC, 0.65) and FDG PET (ICC, 0.46). Conclusion: FAPI PET demonstrated the strongest overall agreement with surgicopathologic PCI and higher detectability than MRI with diffusion-weighted imaging and FDG PET, with preserved performance after chemotherapy, supporting its role for preoperative PC mapping.
引用
- Arçay Öztürk A, Liberale G, Deleu AL, et al. Preoperative Assessment of Peritoneal Carcinomatosis with [68Ga]Ga-FAPI-46 PET/CT: Agreement with Surgicopathologic PCI and Comparison with MRI and [18F]FDG PET/CT. J Nucl Med. 2026. PMID: 42167805. doi:10.2967/jnumed.126.272183
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。